[7] In July 2019, Brian Stuglik was appointed to chief executive officer (CEO) of Verastem Oncology.

[8] Their leading investigational drug is defactinib (VS-6063), is a small-molecule focal adhesion kinase (FAK) inhibitor designed to kill cancer stem cells, intended for the treatment of malignant pleural mesothelioma.

[13] In November 2016, Verastem Oncology licensed global rights from Infinity Pharmaceuticals to duvelisib (IPI-145), a novel inhibitor of PI3K delta and gamma.

[17] The drug label carries a black box warning due to the risk of potentially fatal or serious toxicities: infections, diarrhea or colitis, cutaneous reactions and pneumonitis.

[18] In July 2019, Verastem Oncology signed an exclusive agreement with Sanofi for the commercialization of duvelisib in Russia and CIS, Turkey, the Middle East and Africa.